ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0377

Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies

Maria Angeles Puche Larrubia1, lourdes Ladehesa-Pineda2, María Dolores López Montilla2, Raquel Granados3, Eduardo Collantes4 and Clementina Lopez-Medina5, 1Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, 2Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, 3Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, 4IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 5Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain

Meeting: ACR Convergence 2022

Keywords: Patient reported outcomes, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: The prevalence of late-onset Psoriatic Arthritis (PsA) is increasing in parallel with the progressive aging of the population. The elderly population presents a greater functional deterioration and a greater number of comorbidities. With this study we aim to find clinically relevant differences to predict the evolution and prognosis of the disease depending on the onset of the symptoms to carry out a more exhaustive follow-up. The objective is to evaluate the association of the age at onset of PsA symptoms with the characteristics and burden of the disease.

Methods: Observational study that includes a subgroup of 231 patients with PsA from the REGISPONSER study (Registry of Spondyloarthritis of Spanish Rheumatology) and the RESPONDIA study (Ibero-American Registry of Spondyloarthropathies). Patients were divided into two groups according to the age of PsA onset (early-onset: ≤40 years old and late-onset: ≥60 years old). The characteristics and burden of the disease were compared using the Student’s t-test/Mann-Whitney U test or using the chi-square/Fisher test. Binary logistic regression was performed to determine the factors associated with late-onset psoriatic arthritis.

Results: 231 patients were included [early-onset 179 (77.5%); late-onset 52 (22.5%)] (Table 1). There was a significant higher percentage of men in the late-onset group [94 (62.3%) vs. 38 (86.4%)]. A lower presence of sacroiliitis was found in patients with late-onset PsA [6 (12.2%) vs 58 (32.6%)] as well as enthesitis [5 (9.8%) vs 44 (24.6%)]. Regarding the comorbidities, there was a higher frequency of heart disease among patients with late-onset PsA [4 (7.8%) vs. 0 (0%)]. In respect of the outcome measures, the late-onset group showed higher scores in BASFI [3.3 (2.5) vs. 2.2 (2.2)] and lower scores in FSF12 component [34.6 (8.7) vs. 38.7 (10.5)]. The radiographic indices measured by BASRI showed worse results in those patients with late-onset disease both in the spine [2.9 (3) vs 1.6 (2)] and in the total BASRI [3.4 (3 .4) vs 1.9 (2.4)]. Late-onset PsA is associated with being male (OR 4.4, 95% CI: 1.3, 16.3), greater structural damage (total BASRI) (OR 3.3, 95% CI: 1.3, 8.1), higher frequency of arthritis (upper limbs) (OR 2.8, 95% CI: 1, 7.7), and greater loss of functionality (BASFI) (OR 1.3, 95% CI: 1, 1.6) (Table 2). In addition, it is associated with a shorter diagnostic delay (OR 0.7, 95% CI: 0.6, 0.8), lower frequency of enthesitis (OR 0.1, 95% CI: 0, 0.5), and sacroiliitis (OR 0.06, 95% CI: 0, 0.5).

Conclusion: Our study suggests that the age of onset of PsA was associated with different characteristics of the disease. Patients with late-onset PsA were more frequently males, showed worse functionality and more structural damage. Sacroiliitis and enthesitis were found less frequently in the late-onset group. Quality of life, disease activity and treatments taken were not associated significantly with age of onset. Late-onset PsA is associated with being male, greater structural damage, higher frequency of arthritis (upper limbs), and greater loss of functionality (BASFI). Finally, it is associated with a shorter diagnostic delay, lower frequency of enthesitis and sacroiliitis.

Supporting image 1

Table 1. Description of different characteristics between two groups: early and late onset

Supporting image 2

Table 2. Factors associated with late-onset psoriatic arthritis


Disclosures: M. Puche Larrubia, None; l. Ladehesa-Pineda, None; M. López Montilla, None; R. Granados, None; E. Collantes, None; C. Lopez-Medina, None.

To cite this abstract in AMA style:

Puche Larrubia M, Ladehesa-Pineda l, López Montilla M, Granados R, Collantes E, Lopez-Medina C. Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/differences-in-early-onset-vs-late-onset-psoriatic-arthritis-data-from-the-respondia-and-regisponser-studies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differences-in-early-onset-vs-late-onset-psoriatic-arthritis-data-from-the-respondia-and-regisponser-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology